JP2010526303A - 関節炎及び関連疾病を評価及び治療するためのマトリックスマーカーモデル及び方法 - Google Patents
関節炎及び関連疾病を評価及び治療するためのマトリックスマーカーモデル及び方法 Download PDFInfo
- Publication number
- JP2010526303A JP2010526303A JP2010506711A JP2010506711A JP2010526303A JP 2010526303 A JP2010526303 A JP 2010526303A JP 2010506711 A JP2010506711 A JP 2010506711A JP 2010506711 A JP2010506711 A JP 2010506711A JP 2010526303 A JP2010526303 A JP 2010526303A
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- tnf
- rheumatoid arthritis
- probability
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 86
- 201000010099 disease Diseases 0.000 title claims description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 52
- 239000011159 matrix material Substances 0.000 title abstract description 32
- 206010003246 arthritis Diseases 0.000 title description 22
- 239000003550 marker Substances 0.000 title 1
- 238000011282 treatment Methods 0.000 claims abstract description 102
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 146
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 46
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 44
- 239000005557 antagonist Substances 0.000 claims description 44
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 43
- 229960000485 methotrexate Drugs 0.000 claims description 43
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 25
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 25
- 229960000598 infliximab Drugs 0.000 claims description 24
- 230000006378 damage Effects 0.000 claims description 22
- 210000001503 joint Anatomy 0.000 claims description 18
- 102000037865 fusion proteins Human genes 0.000 claims description 17
- 108020001507 fusion proteins Proteins 0.000 claims description 17
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 16
- 102100032752 C-reactive protein Human genes 0.000 claims description 16
- 230000004071 biological effect Effects 0.000 claims description 13
- 239000003435 antirheumatic agent Substances 0.000 claims description 10
- 206010023232 Joint swelling Diseases 0.000 claims description 9
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 8
- 208000006820 Arthralgia Diseases 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 150000003384 small molecules Chemical class 0.000 claims description 7
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 7
- 229960001940 sulfasalazine Drugs 0.000 claims description 7
- 229960002964 adalimumab Drugs 0.000 claims description 6
- 238000007435 diagnostic evaluation Methods 0.000 claims description 6
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 5
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 claims description 5
- 229960005207 auranofin Drugs 0.000 claims description 5
- 230000003628 erosive effect Effects 0.000 claims description 5
- 210000003743 erythrocyte Anatomy 0.000 claims description 5
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 5
- 229960000681 leflunomide Drugs 0.000 claims description 5
- 238000004393 prognosis Methods 0.000 claims description 5
- 238000004062 sedimentation Methods 0.000 claims description 5
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 5
- ZAVJTSLIGAGALR-UHFFFAOYSA-N 2-(2,2,2-trifluoroacetyl)cyclooctan-1-one Chemical compound FC(F)(F)C(=O)C1CCCCCCC1=O ZAVJTSLIGAGALR-UHFFFAOYSA-N 0.000 claims description 4
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 claims description 4
- 229960001799 aurothioglucose Drugs 0.000 claims description 4
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 4
- 229960002170 azathioprine Drugs 0.000 claims description 4
- 229940015045 gold sodium thiomalate Drugs 0.000 claims description 4
- 229960001743 golimumab Drugs 0.000 claims description 4
- 229960002927 hydroxychloroquine sulfate Drugs 0.000 claims description 4
- 230000000147 hypnotic effect Effects 0.000 claims description 4
- 239000003158 myorelaxant agent Substances 0.000 claims description 4
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 4
- 230000003444 anaesthetic effect Effects 0.000 claims 2
- 230000000202 analgesic effect Effects 0.000 claims 2
- 230000004044 response Effects 0.000 abstract description 7
- 108090000623 proteins and genes Proteins 0.000 description 72
- 108090000765 processed proteins & peptides Proteins 0.000 description 41
- 230000000694 effects Effects 0.000 description 40
- 229920001184 polypeptide Polymers 0.000 description 33
- 102000004196 processed proteins & peptides Human genes 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 24
- 241000219061 Rheum Species 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 20
- 239000012634 fragment Substances 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 239000003446 ligand Substances 0.000 description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 238000011269 treatment regimen Methods 0.000 description 8
- 238000002648 combination therapy Methods 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000009097 single-agent therapy Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000009266 disease activity Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 239000000816 peptidomimetic Substances 0.000 description 5
- 102000057297 Pepsin A Human genes 0.000 description 4
- 108090000284 Pepsin A Proteins 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 229940111202 pepsin Drugs 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000270295 Serpentes Species 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000007423 screening assay Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 101150078577 Adora2b gene Proteins 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108091027757 Deoxyribozyme Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 229940005553 analgesics and anesthetics Drugs 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 102000057041 human TNF Human genes 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000003326 hypnotic agent Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000029226 lipidation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229940035363 muscle relaxants Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- -1 small molecule compound Chemical class 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- XUHRVZXFBWDCFB-QRTDKPMLSA-N (3R)-4-[[(3S,6S,9S,12R,15S,18R,21R,24R,27R,28R)-12-(3-amino-3-oxopropyl)-6-[(2S)-butan-2-yl]-3-(2-carboxyethyl)-18-(hydroxymethyl)-28-methyl-9,15,21,24-tetrakis(2-methylpropyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-27-yl]amino]-3-[[(2R)-2-[[(3S)-3-hydroxydecanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid Chemical compound CCCCCCC[C@H](O)CC(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H]1[C@@H](C)OC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC1=O)[C@@H](C)CC XUHRVZXFBWDCFB-QRTDKPMLSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010051728 Bone erosion Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 238000012352 Spearman correlation analysis Methods 0.000 description 1
- 102100024547 Tensin-1 Human genes 0.000 description 1
- 108010088950 Tensins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229940076085 gold Drugs 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000000551 statistical hypothesis test Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229960003676 tenidap Drugs 0.000 description 1
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Radar Systems Or Details Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91572407P | 2007-05-03 | 2007-05-03 | |
| PCT/US2008/062621 WO2008137828A1 (en) | 2007-05-03 | 2008-05-05 | Matrix marker model and methods for assessing and treating arthritis and related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010526303A true JP2010526303A (ja) | 2010-07-29 |
| JP2010526303A5 JP2010526303A5 (enExample) | 2012-01-26 |
Family
ID=39943976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506711A Pending JP2010526303A (ja) | 2007-05-03 | 2008-05-05 | 関節炎及び関連疾病を評価及び治療するためのマトリックスマーカーモデル及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100145901A1 (enExample) |
| EP (1) | EP2148934B1 (enExample) |
| JP (1) | JP2010526303A (enExample) |
| AT (1) | ATE550443T1 (enExample) |
| AU (1) | AU2008247388A1 (enExample) |
| CA (1) | CA2686260A1 (enExample) |
| WO (1) | WO2008137828A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3042202A1 (en) | 2013-09-03 | 2016-07-13 | Graham, L. Douglas | Treatment methods for rheumatoid arthritis |
| EP4502182A3 (en) * | 2018-01-24 | 2025-07-09 | Genentech, Inc. | Diagnostic and therapeutic methods for the treatment of rheumatoid arthritis (ra) |
| JP7593797B2 (ja) * | 2020-12-08 | 2024-12-03 | キヤノンメディカルシステムズ株式会社 | 解析装置、解析システム及び解析方法 |
| WO2023023338A1 (en) * | 2021-08-19 | 2023-02-23 | Navidea Biopharmaceuticals, Inc. | Compositions and methods for the treatment of rheumatoid arthritis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6187539A (ja) * | 1984-09-19 | 1986-05-02 | ヘルギ・ヴアルデイマーソン | 慢性関節リウマチ患者の予後を補助するための方法及びこのような患者の病態活動の評価を補助するための方法 |
| JP2003508081A (ja) * | 1999-09-08 | 2003-03-04 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 自己免疫疾患における診断および治療方法 |
| US20060141547A1 (en) * | 2004-11-16 | 2006-06-29 | Das Hasi R | Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002022013A1 (en) * | 2000-09-14 | 2002-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing condition of a joint and cartilage loss |
| US7702469B2 (en) * | 2006-04-10 | 2010-04-20 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Systems and methods for predicting an individual's risk of developing rheumatoid arthritis |
-
2008
- 2008-05-05 JP JP2010506711A patent/JP2010526303A/ja active Pending
- 2008-05-05 EP EP08769291A patent/EP2148934B1/en not_active Not-in-force
- 2008-05-05 AU AU2008247388A patent/AU2008247388A1/en not_active Abandoned
- 2008-05-05 AT AT08769291T patent/ATE550443T1/de active
- 2008-05-05 WO PCT/US2008/062621 patent/WO2008137828A1/en not_active Ceased
- 2008-05-05 US US12/595,979 patent/US20100145901A1/en not_active Abandoned
- 2008-05-05 CA CA002686260A patent/CA2686260A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6187539A (ja) * | 1984-09-19 | 1986-05-02 | ヘルギ・ヴアルデイマーソン | 慢性関節リウマチ患者の予後を補助するための方法及びこのような患者の病態活動の評価を補助するための方法 |
| JP2003508081A (ja) * | 1999-09-08 | 2003-03-04 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 自己免疫疾患における診断および治療方法 |
| US20060141547A1 (en) * | 2004-11-16 | 2006-06-29 | Das Hasi R | Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis |
Non-Patent Citations (1)
| Title |
|---|
| JPN6012030559; Ｂｅｎａｚｉｒ Ｓａｌｅｅｍ， Ｓａｌｌｙ Ｒ． Ｃｏｘ， Ｐａｕｌ Ｅｍｅｒｙ: 'Ｂｉｏｍａｒｋｅｒｓ： Ｓｔｒａｔｅｇｉｅｓ ｔｏ ｐｒｅｄｉｃｔｏｕｔｃｏｍｅ ｏｆ ｒｈｅｕｍａｔｏｉｄ ａｒｔｈｒｉｔｉｓ' Ｄｒｕｇ Ｄｉｓｃｏｖｅｒｙ Ｔｏｄａｙ Ｔｈｅｒａｐｅｕｔｉｃ Ｓｔｒａｔｅｇｉｅｓ Ｖｏｌｕｍｅ．３， Ｎｏ．１, 2006, Ｐａｇｅｓ．１１-１６ * |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1140797A1 (en) | 2010-10-22 |
| EP2148934A1 (en) | 2010-02-03 |
| CA2686260A1 (en) | 2008-11-13 |
| ATE550443T1 (de) | 2012-04-15 |
| EP2148934B1 (en) | 2012-03-21 |
| EP2148934A4 (en) | 2010-07-07 |
| US20100145901A1 (en) | 2010-06-10 |
| AU2008247388A1 (en) | 2008-11-13 |
| WO2008137828A1 (en) | 2008-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kolkhir et al. | Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases | |
| Fury et al. | Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance | |
| Sieper et al. | Axial spondyloarthritis | |
| Finzel et al. | Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis | |
| WO2008156865A2 (en) | Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease | |
| Kang et al. | Efficacy of novel bispecific antibody targeting TNF-α/CXCL10 in the treatment of experimental arthritis | |
| Kawashiri et al. | Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan | |
| JP5914587B2 (ja) | 抗腫瘍壊死因子アルファ（ｔｎｆ）治療に対する応答性の予想のためのバイオマーカー | |
| EP2148934B1 (en) | Matrix marker model and methods for assessing and treating rheumatoid arthritis | |
| TW202106712A (zh) | 類風溼性關節炎之診斷及治療方法 | |
| JP7418324B2 (ja) | Ｆｇｆ－１８化合物に対する反応性を予測する炎症バイオマーカー | |
| US7709215B2 (en) | Method for diagnosing and treating acute joint injury | |
| BR112021015596A2 (pt) | Distúrbios mediados pelo interferon tipo i | |
| HK1140797B (en) | Matrix marker model and methods for assessing and treating rheumatoid arthritis | |
| Cobo-Ibanez et al. | Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis | |
| Alshamary et al. | Comparison of the effects of Methotrexate and Etanercept on RANKL and OPG as Bone Metabolism Biomarkers in patients with Rheumatoid Arthritis | |
| AU2008260077B2 (en) | Methods and kits for diagnosing and treating acute joint injury | |
| KR20140109956A (ko) | 테나신-c 및 류마티스 관절염에서의 이의 용도 | |
| Kawakami | Shin-ya Kawashiri1, 2, 3, Yushiro Endo2, 3, Ayako Nishino2, 3, Momoko Okamoto2, Sosuke Tsuji2, Ayuko Takatani2, Toshimasa Shimizu2, Remi Sumiyoshi2, Tomohiro Koga2, Naoki Iwamoto2, Kunihiro Ichinose2, Mami Tamai2, Hideki Nakamura2, Tomoki Origuchi2, Toshiyuki Aramaki3, Yukitaka Ueki3, Tamami Yoshitama3, Nobutaka Eiraku3, Naoki Matsuoka3, Akitomo Okada3, Keita Fujikawa3, Hiroaki Hamada3, Shuji Nagano3, Yoshifumi Tada3 and | |
| AU2010313318A1 (en) | Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients | |
| Warzocha et al. | Polymyalgia rheumatica-risk factors, pathogenesis, diagnostic methods, treatment-new literature reports | |
| Fitton | Phenotyping DAS28 and Refractory Rheumatoid Arthritis | |
| US11674951B2 (en) | Methods for identifying a treatment for rheumatoid arthritis | |
| MUÑOZ-VILLAFRANCA et al. | Infliximab and Adalimumab Monitoring versus Clinical Control during Maintenance Therapy in Patients with Inflammatory Bowel Disease | |
| Rostom et al. | Assessment of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving tocilizumab using low field MRI. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110330 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111201 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20120522 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120529 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120607 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120619 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120918 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120925 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130514 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131029 |